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Milk: an epigenetic amplifier 




Single-nucleotide polymorphisms within intron 1 of the FTO (fat mass and obesity-associated) gene are associated 
with enhanced FTO expression, increased body weight, obesity and type 2 diabetes mellitus (T2DM). The N6-methy-
ladenosine (m6A) demethylase FTO plays a pivotal regulatory role for postnatal growth and energy expenditure. The 
purpose of this review is to provide translational evidence that links milk signaling with FTO-activated transcription 
of the milk recipient. FTO-dependent demethylation of m6A regulates mRNA splicing required for adipogenesis, 
increases the stability of mRNAs, and affects microRNA (miRNA) expression and miRNA biosynthesis. FTO senses 
branched-chain amino acids (BCAAs) and activates the nutrient sensitive kinase mechanistic target of rapamycin 
complex 1 (mTORC1), which plays a key role in translation. Milk provides abundant BCAAs and glutamine, critical 
components increasing FTO expression. CpG hypomethylation in the first intron of FTO has recently been associated 
with T2DM. CpG methylation is generally associated with gene silencing. In contrast, CpG demethylation generally 
increases transcription. DNA de novo methylation of CpG sites is facilitated by DNA methyltransferases (DNMT) 3A and 
3B, whereas DNA maintenance methylation is controlled by DNMT1. MiRNA-29s target all DNMTs and thus reduce 
DNA CpG methylation. Cow´s milk provides substantial amounts of exosomal miRNA-29s that reach the systemic 
circulation and target mRNAs of the milk recipient. Via DNMT suppression, milk exosomal miRNA-29s may reduce the 
magnitude of FTO methylation, thereby epigenetically increasing FTO expression in the milk consumer. High lacta-
tion performance with increased milk yield has recently been associated with excessive miRNA-29 expression of dairy 
cow mammary epithelial cells (DCMECs). Notably, the galactopoietic hormone prolactin upregulates the transcription 
factor STAT3, which induces miRNA-29 expression. In a retrovirus-like manner milk exosomes may transfer DCMEC-
derived miRNA-29s and bovine FTO mRNA to the milk consumer amplifying FTO expression. There is compelling 
evidence that obesity, T2DM, prostate and breast cancer, and neurodegenerative diseases are all associated with 
increased FTO expression. Maximization of lactation performance by veterinary medicine with enhanced miRNA-29s 
and FTO expression associated with increased exosomal miRNA-29 and FTO mRNA transfer to the milk consumer may 
represent key epigenetic mechanisms promoting FTO/mTORC1-mediated diseases of civilization.
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Background
FTO, fat mass- and obesity-associated gene (MIM 
612938) maps to chromosome 16q12.2 and is widely 
expressed in a variety of human tissues with highest 
levels detected in the brain, pancreatic islets, and the 
liver [1, 2]. The 505 amino acid-long human FTO and 
its orthologs are present in vertebrate evolution for at 
least 450 million years [3]. FTO mRNA is most abun-
dant in hypothalamic nuclei governing energy balance 
[4, 5]. FTO was identified as an obesity susceptibility 
gene by several large-scale genome association studies 
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first intron of FTO are highly associated with obesity and 
obesity-related traits [1, 6, 7]. In various populations FTO 
has been confirmed to be a major risk gene promoting 
obesity [8–19]. Obesity is a well-known risk factor for the 
development of type 2 diabetes mellitus (T2DM). Indeed, 
FTO has been identified as a critical T2DM susceptibil-
ity locus [20–28]. Obesity and T2DM-associated genetic 
variations of FTO are associated with increased primary 
transcript levels of FTO mRNA [14, 29, 30].
Not only genetic polymorphisms of FTO, but also the 
methylation status of FTO, especially CpG hypometh-
ylation of intron 1 has been linked to increased T2DM 
prevalence [31]. It is not known whether demethylated 
CpG loci in intron 1 map directly to regulatory regions 
and SNPs. Notably, FTO methylation in human pancre-
atic islets of T2DM patients is significantly reduced com-
pared to healthy controls [32]. Thus, not only genetic but 
also epigenetic modifications of FTO appear to modify 
FTO expression. It is well appreciated that dietary factors 
induce epigenetic alterations, which have pivotal long-
term biological consequences [33].
This paper highlights the potential role of milk as an 
epigenetic modifier of the human genome paying special 
attention to cow milk-mediated overactivation of FTO 
and its impact on the transcriptome of the human milk 
consumer.
Review
FTO regulates fetal and postnatal growth
The FTO gene is widely expressed in both fetal and adult 
tissues [1]. The mouse mutant Fused toes (Ft) is a domi-
nant trait characterized by partial syndactyly of the fore-
limbs and massive thymic hyperplasia in heterozygotes 
[34]. Homozygous Ft/Ft embryos die at midgestation and 
exhibit absent Fto expression in fibroblasts [35]. Fto-null 
mice exhibit postnatal growth retardation and a signifi-
cant reduction in adipose tissue and lean body mass [36]. 
Mice lacking Fto display postnatal growth retardation 
with shorter body length, lower body weight, lower bone 
mineral density, and reduced serum levels of insulin-like 
growth factor 1 (IGF-1) [37]. Remarkably, specific Fto 
deletion in the central nervous system (CNS) results in 
a similar phenotype as whole body Fto deletion pointing 
to a crucial role of Fto in the CNS to promote postnatal 
growth [37]. Studies of human cultured skin fibroblasts 
from subjects with an R316Q mutation that inactivates 
FTO enzymatic activity showed impaired proliferation 
and accelerated senescence [2].
Milk is the exclusive nutrient environment provided 
by mammals promoting postnatal growth during the 
lactation period [38]. Milk activates the nutrient-sen-
sitive kinase mechanistic target of rapamycin com-
plex 1 (mTORC1), which induces mTORC1-dependent 
translation [39]. FTO plays a crucial role in mRNA tran-
scription [40], a requirement for mTORC1-dependent 
translation. Thus, from a mechanistic point of view milk 
has to interact with both FTO and mTORC1 of the milk 
recipient.
FTO controls energy homeostasis and protein intake
In mice, overexpression of Fto leads to a dose-dependent 
increase in body and fat mass, irrespective of whether 
mice are fed a standard or a high-fat diet [41]. However, 
mice with increased Fto expression on a high-fat diet 
develop glucose intolerance [41]. FTO plays a critical 
role in controlling feeding behavior and energy expendi-
ture [42]. SNPs of FTO have been linked to higher energy 
intake and increased appetite [40, 43–49]. FTO mRNA is 
present mainly in sites related to hunger/satiation con-
trol [50]. Changes in hypothalamic FTO expression are 
associated with cues related to energy intake [50]. Fast-
ing induced cytoplasmic Fto expression in some neurons 
of rat hypothalamus [51], whereas under conditions of 
nutrient availability Fto is concentrated in nuclear speck-
les [30]. Interestingly, FTO has been found to mediate 
circadian rhythms and inhibits CLOCK-BMAL1-induced 
transcription [52]. The BMI-increasing allele of FTO 
showed a significant association with higher dietary pro-
tein intake [53].
Epigenetic regulation of FTO
The FTO and RPGRIP1L genes are located on the long 
arm of chromosome 16 and share a CpG island with 51 
CpG dinucleotides. The obesity-associated SNPs of FTO 
are located in intron 1 [30]. FTO methylation has been 
linked to environmental influences such as dietary fac-
tors [29]. It is generally accepted that CpG hypometh-
ylation increases transcriptional activity, whereas DNA 
CpG methylation is associated with gene silencing [54]. 
Recent evidence indicates that CpG hypomethylation is 
generally associated with gene silencing at CpG-island 
promotors of genes, whereas high levels of intragenic 
methylation are associated with increased transcription 
[55, 56]. There is compelling evidence that FTO SNPs 
of intron 1 are associated with increased levels of FTO 
expression [14, 29, 30]. Toperoff et al. [57] demonstrated 
that a CpG site in the first intron of the FTO gene showed 
small but significant hypomethylation in T2DM patients 
relative to controls. The same group later confirmed that 
CpG sites in the first intron of FTO of peripheral blood 
leukocytes exhibited significant hypomethylation in 
T2DM cases relative to controls [31]. Furthermore, sig-
nificant FTO hypomethylation has been confirmed in 
human pancreatic islets of T2DM patients compared to 
healthy controls [32]. Importantly, decreased methylation 
of FTO CpG11 sites have been associated with increased 
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FTO mRNA expression [58]. Thus, preliminary indirect 
evidence supports the view that hypomethylation of spe-
cific CpG sites of the FTO gene enhance FTO expression. 
Thus, a critical question arises: Do we have evidence that 
milk, the exclusive and sufficient nutrient environment of 
a newborn mammal, shape the epigenome and transcrip-
tome of its recipient by increasing FTO expression?
Milk miRNA‑29s: potential suppressors of DNA 
methyltransferases
Secreted exosomal miRNAs represent an important 
layer of gene regulation and intercellular communication 
[59–64]. MiRNAs bind through partial sequence homol-
ogy to the 3′-untranslated region (UTR) of their target 
mRNAs and cause either translational block or mRNA 
degradation [64]. Melnik et al. [38] have suggested that 
milk functions like an “epigenetic transfection system” 
via transfer of milk-derived exosomes. Of all human 
body fluids, milk contains the highest amount of RNAs 
[65]. In fact, mRNA- and miRNA-containing exosomes 
have been discovered in human milk [66–69], bovine 
milk [70–74], and milk of other mammals [75–78]. An 
accumulating body of evidence supports the view that 
milk miRNAs are bioactive compounds in foods [79]. 
Whereas a recent study in a mouse model screening for 
selected mouse milk miRNAs (miRNA-375, miRNA-
200c/141) revealed rapid milk miRNA degradation in 
the intestinal fluid [80], Wolf et  al. [81] demonstrated 
that bovine milk exosomes including miRNA-29b and 
miRNA-200c are taken up by human intestinal cells via 
endocytosis depending on exosome and cell surface gly-
coproteins. It has been confirmed in the suckling wal-
laby that highly expressed milk miRNAs are detected 
at signifcant higher levels in the neonate blood serum, 
confirming that milk miRNAs are absorbed in the gut 
of the young [78]. Milk is obviously a unique mamma-
lian transfer system of exosomal miRNAs and mRNAs 
from the mother to her infant [38, 82]. MiRNAs of 
commercial cow´s milk survive processing such as pas-
teurization, homogenization and refrigeration for at 
least 2  weeks [83]. Remarkably, bovine milk exosomes 
are highly resistant against harsh degrading conditions 
[72, 77]. Bovine milk exosomes containing miRNAs 
and mRNAs are taken up by human macrophages [72]. 
Baier et al. [84] provided evidence that cow’s milk miR-
NAs are absorbed in biologically meaningful amounts 
from nutritionally relevant doses of cow’s milk and affect 
gene expression in peripheral blood mononuclear cells, 
HEK-293 kidney cell cultures, and mouse livers. Impor-
tantly, bovine milk miRNA-29b, which is identical with 
human miRNA-29b (http://www.microrna.org), is taken 
up by blood mononuclear cells of the milk consumer in a 
dose-dependent manner and modifies mRNA expression 
such as RUNX2 [84]. These observations imply that 
milk-derived miRNA-29b may also affect other miRNA-
29b targets such as the mRNAs of the DNA demethyl-
ase (DNMT) 3A and 3B [85]. Enforced expression of 
miRNA-29b results in marked reduction of the expres-
sion of DNMT1, DNMT3A, and DNMT3B at both 
mRNA and protein levels.
It has been demonstrated that miRNA-29b indirectly 
downregulates DNMT1 by targeting Sp1, a transacti-
vator of DNMT1 [86–90]. MiRNA-21, another abun-
dant miRNA type of bovine milk [70, 74] which shares 
sequence homology with human miRNA-21 (http://www.
microrna.org), indirectly downregulates DNMT1 by tar-
geting RASGRP1 [91]. It is noteworthy to mention that 
murine mammary miRNA-21 expression is controlled by 
prolactin-induced upregulation of STAT5 [92].
Thus, milk appears to modify the infant’s epigenome 
via suppressing DNA de novo methylation (DNMT3A 
and DNMT3B) as well as DNA maintenance methyla-
tion (DNMT1) [54]. Physiologically, milk consumption 
is an early life environmental exposure that may modify 
epigenetic signatures [93]. DNA methylation plays a criti-
cal role in genomic imprinting during preimplantation 
development [94–100] as well as during early differentia-
tion [101]. Remarkably, early nutrition during the post-
natal period apparently influences the adult phenotype 
via DNA methylation [102–104]. It is conceivable that 
milk via miRNA-29b/miRNA-21/DNMT signaling pro-
motes CpG demethylation at intron 1 of FTO resulting in 
increased expression of FTO, which functions as a criti-
cal amplifier of the transcriptional machinery for postna-
tal growth.
Human breast milk also contains and transfers exoso-
mal miRNA-29b and miRNA-21 to the suckling infant 
[66–69, 105]. At present, no quantitative studies are 
available which allow a comparison of the amounts of 
miRNA-29b and miRNA-21 of commercial cow´s milk 
and human breast milk, respectively.
Essential amino acids increase FTO expression
Milk proteins are a rich nutrient source of branched-
chain essential amino acids (BCAAs) and glutamine [106, 
107]. In mouse hypothalamic N46 cells, mouse embry-
onic fibroblasts (MEFs) and in human HEK293 cells, 
FTO mRNA and protein levels are significantly downreg-
ulated by total amino acid deprivation [108]. Remarkably, 
FTO functions as an amino acid sensor [109] and couples 
BCAA availability to mTORC1 signaling [110], which 
plays a crucial role in translation [39]. In contrast, FTO 
knockdown results in the upregulation of genes involved 
in cellular response to starvation [30] such as ATG5 and 
BECN1, which initiate autophagy by inhibiting mTORC1 
and mTORC1-dependent translation [111, 112].
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The availability of BCAAs plays a fundamental role in 
mTORC1 activation [113–120]. The rate-controlling and 
irreversible step of BCAA catabolism is catalyzed by 
the multienzyme mitochondrial branched-chain α-keto 
acid dehydrogenase (BCKD) [121]. The dihydrolipoyl 
transacylase (E2) forms the core of the BCKD complex 
and is of critical importance for BCKD activity [122]. 
Notably, miRNA-29b targets the mRNA of dihydroli-
poyl transacylase (E2) and thereby inhibits BCKD activ-
ity and mitochondrial BCAA catabolism [123]. Thus, 
milk miRNA-29b enhances the availability of BCAAs, 
an important requirement for FTO expression [108]. It 
is conceivable that milk-mediated transfer of BCAAs 
and miRNA-29b-mediated preservation of BCAAs may 
enhance the recipient´s FTO- and mTORC1 activity.
It is important to note that human breast milk con-
tains 1.2 g/100 mL milk protein in comparison to cow´s 
milk that contains 3.5 g protein/100 mL. In comparison 
to human breast milk, equivalent volumes of cow´s milk 
transfer three times more BCAAs to the milk consumer 
[38, 39] and thus may overstimulate BCAA-driven FTO 
activation.
FTO controls the RNA methylome
FTO belongs to the superfamily of Fe(II) 2-oxoglutarate 
(2-OG)-dependent dioxygenases [4]. FTO catalyzes the 
demethylation of 3-methylthymine and 3-methyluracil 
in single-stranded DNA and RNA to thymine and uracil 
[124]. Jia et al. [125–127] recently detected that N6-meth-
yladenosine (m6A) in nuclear RNA is a major substrate of 
the demethylase FTO. The m6A mark is the most preva-
lent internal (non-cap) modification present in mRNAs 
of all higher eukaryotes [128, 129]. The discovery that 
FTO is an m6A demethylase indicates that this modifica-
tion is reversible and dynamically regulated, suggesting 
that reversible RNA methylation may affect gene expres-
sion and cell fate decisions by modulating multiple RNA-
related cellular pathways, which potentially provide rapid 
responses to environmental signals such as nutrient and 
especially milk availability in mammals [129] (Table 1).
Berulava et  al. [30] demonstrated that FTO is highly 
enriched in nuclear speckles, which serve as for storage 
and modification of pre-mRNA splicing factors. Pro-
posed functions for m6A modification include mRNA 
splicing, export, stability, and immune tolerance [130]. 
FTO overexpression greatly reduced the levels of m6A in 
cellular RNA underlining that m6A is a major physiologic 
target of FTO [125–127].
Wang et  al. [131] recently demonstrated that m6A is 
selectively recognized by the human YTH domain family 
2 (YTHDF2) protein to promote mRNA degradation. Liu 
et al. [132] showed that m6A-dependent RNA structural 
Table 1 Biological impacts of FTO from fetal to adult life
FTO expression Biological alterations References
Increased placental FTO expression Increased fetal and birth weight [226–228]
Absent FTO expression (fused toes mutant mice) Murine embryos die at midgestation [34, 35]
Fto-null mice Postnatal growth retardation, reduced adipose tissue and lean body mass, 
shorter body length, lower bone mineral density, lower serum IGF-1
[36, 37]
Fto deletion in murine CNS Postnatal growth retardation [37]
SNPs with higher FTO expression Higher energy intake, increased appetite, higher dietary protein intake [40, 43–49, 53]
Hypothalamic FTO expression Regulation of hunger/satiation, energy intake and circadian rhythm [50–52]
Early hypothalamic FTO over-expression in the rat Postweaning hyperphagia [155]
Fto over-expression in mice Increase in body and fat mass, glucose intolerance during high-fat diet, 
metabolic syndrome
[41, 213]
FTO over-expression Increased gluconeogenesis [266]
FTO over-expression Increased adipogenesis, reduced thermogenesis of preadipocytes, insulin 
resistance
[146, 249, 251, 268]
FTO deficiency in adipocytes Increased expression of UCP-1 (thermogenin), induction of BAT phenotype 
with increased thermogenesis
[252]
Obesigenic FTO variants Increased BMI in children at 8 yrs, higher risk of early menarche at 12 yrs [234, 244]
Obesigenic FTO variants Increased BMI and obesity in adults [8–19]
Obesigenic FTO variants Increased risk of T2DM in adults [20–28]
FTO rs9939609 A-allele Increased risk of coronary heart disease [214, 215]
Obesigenic FTO variants Increased risk of cancer, especially PCa and BCa [276, 277, 291–298]
Obesigenic FTO SNPs Reduction in frontal lobe volume of the brain, impaired verbal fluency, 
increased risk of AD
[319–323]
FTO rs9939609 SNP Reduced leucocyte telomere length, accelerated aging [342]
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switches regulate RNA–protein interactions. m6A alters 
the local structure in RNA and long non-coding RNA 
to facilitate binding of heterogeneous nuclear ribonu-
cleoprotein C (HNRNPC), an abundant nuclear RNA-
binding protein responsible for pre-mRNA processing 
[133–137]. These m6A-switch-regulated HNRNPC-
binding activities affect the abundance as well as alter-
native splicing of target mRNAs, underlining the pivotal 
regulatory role of m6A-switches on gene expression and 
RNA maturation [132]. Thus, dynamic m6A modifica-
tions are recognized by selective binding proteins, which 
affect the translation status and lifetime of mRNAs. m6A 
methylation not only occurs in mRNA but also in riboso-
mal RNA (rRNA), transfer RNA (tRNA), small nucleolar 
RNA (snoRNA), long non-coding RNA (lncRNA), and 
miRNAs [138–142]. Overexpression of FTO in HeLa 
cells reduced the level of m6A in purified poly (A) RNA 
by 18 %, whereas FTO knockdown increased m6A levels 
by 23 % in poly (A) mRNA [138, 143]. Adenosine meth-
yltransferases (‘writers’), m6A demethylating enzymes 
(‘erasers’) such as FTO and ALKBH5 and m6A-binding 
proteins (‘readers’) thus define cellular pathways for the 
post-transcriptional regulation of mRNAs. The m6A 
methylation pattern thus constitutes the mRNA ‘epitran-
scriptome’ [138, 143].
Furthermore, the m6A status modifies the interaction 
of miRNAs with their target mRNAs. A significant por-
tion of m6A occurs in close vicinity to the 3´UTRs of 
mRNA transcripts, which correlate with their miRNA 
binding sites [138]. Knockdown of FTO affects the steady 
state levels of several miRNAs pointing to a further layer 
of FTO-dependent posttranscriptional regulation of gene 
expression [142]. As miRNAs inhibit their target mRNAs, 
decreased expression of FTO suppresses global mRNA 
transcription, whereas overexpression of FTO enhances 
transcriptional activity. Moreover, m6A marks act as a 
key post-transcriptional modification initiating miRNA 
biogenesis [144].
Milk, lactation’s nutrient system operating during the 
postnatal growth period between mother and infant may 
shape the infants epitranscriptome via RNA m6A dem-
ethylation to increase transcription, required for postna-
tal growth, body mass, protein and fat mass accretion.
FTO regulates adipogenesis‑related RUNX1T1 mRNA 
splicing
Recent evidence links FTO overexpression to enhanced 
expression of the pro-adipogenic short isoform of the 
transcription factor RUNX1T1. FTO controls mRNA 
splicing by regulating the ability of the splicing factor 
SRSF2 to bind to mRNA in an m6A-dependent manner 
[145]. The pro-adipogenic short isoform of RUNX1T1 
stimulates mitotic clonal expansion (MCE) of MEFs and 
thus enhances adipocyte numbers [146]. In contrast, 
mRNA m6A methylation downregulates adipogenesis in 
porcine adipocytes [147]. Thus, FTO negatively regulates 
m6A levels and positively regulates adipogenesis, while 
methyltransferase-like 3 (METTL3), which catalyzes the 
formation of m6A in RNA [148], positively correlates 
with m6A levels and suppresses adipogenesis [147]. In 
accordance, long-term feeding of commercial pasteur-
ized cow´s milk to young mice increased body weight, 
caloric intake, and epididymal fat mass as compared to 
milk-free controls [149].
FTO controls appetite via ghrelin mRNA demethylation
The “hunger hormone” ghrelin functions as a neuropep-
tide in the CNS and regulates energy homeostasis [150, 
151]. Ghrelin increases appetite by triggering recep-
tors in the arcuate nucleus [152]. The ghrelin receptor is 
expressed in many brain areas important for feeding con-
trol, including hypothalamic nuclei involved in energy 
balance regulation and reward-linked areas such as the 
ventral tegmental area (VTA) [153]. It has recently been 
recognized that ghrelin signaling at the level of the mes-
olimbic system is one of the key molecular substrates 
that provides a physiological signal connecting gut and 
reward pathways [153]. In some way, milk intake should 
trigger ghrelin signaling enhancing appetite and reward 
pathways to secure postnatal food intake for mammalian 
development.
Karra et  al. [154] found that subjects homozygous for 
the FTO “obesity-risk” rs9939609 A allele have dysregu-
lated circulating levels of acyl-ghrelin and attenuated 
postprandial appetite reduction. FTO overexpression 
reduced ghrelin mRNA m6A methylation, concomitantly 
increasing ghrelin mRNA and peptide levels. Periph-
eral blood cells from homozygous (AA) subjects for the 
FTO “obesity-risk” rs9939609 variant exhibited increased 
FTO mRNA, reduced ghrelin m6A mRNA, and increased 
ghrelin mRNA abundance [154].
At weaning, hypothalamic FTO mRNA expression was 
increased significantly in the offspring of obese female 
Sprague–Dawley rats and FTO was correlated with both 
visceral and epididymal fat mass [155]. In these rats 
early hypothalamic FTO overexpression contributes to 
postweaning hyperphagia [155]. Among carriers of the 
risk allele of the FTO SNP rs9939609 an association was 
found between BMI growth and the duration of exclu-
sive breastfeeding (EXBF). In girls, EXBF interacts with 
the SNP at baseline and can reverse the increase in BMI. 
In boys, EXBF reduces BMI both in carriers and non-
carriers of the risk allele with an association found after 
10  years of age. Six months of EXBF will put the boys’ 
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BMI growth curves back to the normal range [156]. Thus, 
human breast milk appears to control the appropriate 
postnatal magnitude of FTO expression and activity.
FTO couples leucyl‑tRNA synthase to mTORC1
FTO expression is of pivotal importance for mTORC1 
signaling and represents the critical mechanistic link 
between transcription and translation. MEFs of FTO-
deficient mice (Fto−/− mice) exhibit slower growth rates 
and reduced mRNA translation compared with wild-
type MEFs [110]. Postnatal growth retardation and sig-
nificant reduction in adipose tissue and lean body mass 
has been observed in Fto−/− mice [36]. Severe growth 
retardation has also been observed in humans with 
homozygous FTO loss-of-function mutations [2]. Dur-
ing tRNA charging with amino acids amino-acyl-tRNA 
synthetases (AARS) work together as part of the multi-
synthetase complex (MSC), which is essential for mRNA 
translation [157–159]. In higher eukaryotic systems, 
several different AARSs including leucyl-tRNA syn-
thetase form a macromolecular protein complex with 
three nonenzymatic cofactors AIMP1/p43, AIMP2/p38, 
and AIMP3/p18 [159]. Notably, Fto−/− MEFs exhibit 
reduced protein levels of MSC components [110]. A key 
role for mTORC1 activation plays leucyl-tRNA synthase 
(LRS) [160, 161]. LRS has been proposed to function as 
an intracellular amino acid sensor [161]. In yeast, LRS 
Cdc60 interacts with the Rag GTPase Gtr1 of the EGOC 
in a leucine-dependent manner [160]. This interaction 
is necessary and sufficient to mediate leucine signaling 
to TORC1 and is disrupted by the engagement of Cdc60 
in editing mischarged tRNA(Leu) [160]. Han et al. [161] 
demonstrated that LRS directly binds to Rag GTPase, 
the mediator of amino acid signaling to mTORC1, in 
an amino acid-dependent manner and functions as a 
GTPase-activating protein (GAP) for Rag GTPase to acti-
vate mTORC1. Importantly, FTO-deficient MEFs exhibit 
reduced LRS protein expression [110].
It is tempting to speculate that FTO-mediated dem-
ethylation of m6A in leucyl-tRNA may modify LRS reg-
ulatory functions. Furthermore, Lo et  al. [162] detected 
splice variants of LRS, which differ in catalytic activity. 
It is possible that LRS mRNA splice variants modify the 
affinity for leucine binding, thereby change the func-
tional interaction of LRS with Rag GTPase activating 
mTORC1. This mRNA-splicing dependent mechanism 
may resemble the generation RUNX1T1 short splice vari-
ants observed in the regulation of adipogenesis [145, 146] 
(Table 2).
Dairy cattle FTO mutations increase milk yield
mRNA abundance of FTO in mammary epithelial cells 
has been shown during lactation of the rabbit [163]. 
Recently, genetic variations of bovine FTO have been 
identified that increase milk fat and protein yield in Ger-
man Holstein dairy cattle [164]. Five SNPs and two hap-
lotype blocks in a 725 kb region covering FTO and the 
neighboring genes RPGRIP1L, U6ATAC, and 5 S rRNA 
were associated with milk fat and protein yield [164]. 
Furthermore, Sorbolini et al. [165] confirmed that FTO 
belongs to the selection signatures in Piemontese and 
Marchigiana cattle known to affect productive traits.
Physiologically cattle digest grass, whereas high perfor-
mance dairy cows are fed with soybean and grain concen-
trates that provide higher amounts of BCAAs promoting 
FTO expression and FTO-driven transcription increas-
ing lactation performance. Thus, increased expression of 
FTO in DCMECs increases milk yield.
Table 2 Biological functions of the m6A demethylase FTO
Epigenetic FTO functions Transcriptional effects References
FTO-catalyzed demethylation of m6A in
mRNAs
Increased transcription and mRNA stability, modification of m6A-dependent alternative 
splicing and miRNA binding to target mRNAs
[125–127, 138–143]
FTO over-expression Generation of the pro-adipogenic short isoform of RUNX1T1 promoting MCE increasing 
adipocyte numbers
[145, 146]
Increased FTO mRNA Reduction of ghrelin mRNA m6A methylation resulting in increased ghrelin mRNA abun-
dance
[154]
FTO-deficient MEFs Reduced protein expression of the mTORC1 activator leucyl-tRNA synthetase [110]
Increased FTO expression Association of FTO CpG hypomethylation in T2DM with recuded m6A levels in mRNA of 
T2DM patients
[31, 32, 265]
FTO over-expression Increased expression of C/EBPβ mRNA, the key transcription factor of gluconeogenesis 
and adipogenesis
[266, 267]
FTO over-expression Loss of stem cell self-renewal capability [207]
FTO over-expression Increased expression of PRL mRNA enhancing PIP expression involved in PC and BC 
progression
[185–187]
FTO over-expression Interaction with APO ϵ4, increasing the risk of AD [321]
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Is bovine FTO mRNA retroconverted into the human 
genome?
The human FTO gene shares 86.8 % amino acid sequence 
homology with bovine FTO [3]. It is thus conceivable 
that upregulated bovine FTO mRNA of high perfor-
mance DCMECs may reach the human milk consumer 
via intake of mRNA containing milk exosomes. RNA-
dependent DNA polymerase activity (reverse tran-
scriptase, RT) has been detected in the milk of several 
mammalian species including humans [166–173]. Impor-
tantly, milk exosomes contain both mRNA and RT [174]. 
Around 42  % of the human genome is made up of ret-
rotransposons, which operate via RNA intermediates 
[175]. Recently, Irmak et al. [176] provided translational 
evidence for the hypothesis that milk exosomes function 
as an RNA-based gene delivery system between mother 
and infant. This implies that bovine milk exosomes 
via transfer of RT and mRNA—such as bovine FTO 
mRNA—may affect the composition and function of 
retrotransposons of the human milk consumer. The 
integration of milk-derived bovine FTO mRNA into 
the human genome via retrotransposition may be a fur-
ther mechanism amplifying FTO gene expression [177] 
(Fig.  1). Most transposable elements are silenced by 
CpG methylation. Potential milk-miRNA-29/DNMT-
mediated changes of the epigenetic state of transposable 
elements may affect regions encompassing neighboring 
genes [102]. Evidence has been presented that transpos-
able elements are targets for early nutritional effects on 
epigenetic gene regulation [102].
Bovine miRNA‑29 increases lactation performance
MiRNA-29a and miRNA-29b have been identified as 
important miRNAs involved in the regulation of lacta-
tion [178, 179]. Bian et  al. [180] investigated the roles 
of miRNA-29s in epigenetic regulation of DCMECs. 
They showed that miRNA-29s regulate the DNA meth-
ylation level by inversely targeting both DNMT3A and 
DNMT3B in DCMECs. MiRNA-29  s stimulate lacta-
tion via decreasing the promoter methylation of CSN1S1 
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Fig. 1 Working model presenting milk-mediated epigenetic activation of FTO-driven transcription. Milk functions in analogy to a retroviral infection 
via exosome transfer to the cells of the milk recipient. Milk exosomes transport bioactive miRNA-29s that reduce the expression of DNA methyl-
transferases (DNMTs) resulting in epigenetic activation of human FTO via DNA hypomethylation. Bovine milk exosomes apparently transfer bovine 
FTO mRNA and reverse transcriptase (RT) that may result in bFTO mRNA retroconversion into the human genome. (1) Milk provides abundant 
amounts of branched-chain amino acids (BCAAs) and glutamine (Gln) that activate FTO and mTORC1. (2) Bovine milk production is enhanced by 
increased expression of miRNA-29s and certain bFTO gene polymorphisms. (3) Dairy cow feeding with BCAA-enriched concentrated feedingstuffs 
upregulates bFTO mRNA and protein expression. Efforts of veterinary medicine intended to maximize milk yield associated with increased dairy 
cow mammary epithelial cell (DCMEC) transcription have an epigenetic impact on FTO expression of the human milk consumer. FTO, the criti-
cal m6A demethylase, upregulates transcription, adipogenesis, and gluconeogenesis promoting postnatal growth
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(casein-α s1), EIF5 (E74-like factor 5), PPARγ (peroxi-
some proliferator-activated receptor-γ), SREBP1 (sterol 
regulatory element binding protein-1) and GLUT1 (glu-
cose transporter 1) and increase triglyceride biosynthesis 
[180]. In contrast, inhibition of miRNA-29s causes global 
DNA hypermethylation and increases the methylation 
levels of the promoters of important lactation-related 
genes CSN1S1, ElF5, PPARγ, SREBP1 and GLUT1 and 
reduces the secretion of lactoprotein, triglycerides and 
lactose by DCMECs [180]. It is thus conceivable that 
high expression of bovine miRNA-29b via inhibition of 
DNMT3A and DNMT3B in high performance dairy cows 
also decreases bovine FTO methylation thereby increas-
ing FTO-dependent transcription. Furthermore, select-
ing cows with high miRNA-29 expression may increase 
the miRNA-29 content of commercial milk exosomes. 
Thus, milk enriched in miRNA-29b and bovine FTO 
mRNA may epigenetically enhance the FTO expression 
of the milk consumer (Fig. 1).
FTO catalyzes prolactin mRNA demethylation
Prolactin (PRL) is the central hormone in female mam-
mals to produce milk [181, 182].
PRL is essential for maintaining lactation and is galac-
topoietic in dairy cows [183, 184]. m6A residues in an 
intron-specific region of bovine PRL pre-mRNA have 
been identified [185–187]. Treatment of CHO cells 
with the methylation inhibitor neplanocin resulted in a 
4–6fold increase in nuclear bPRL precursor compared 
to control cells [186]. FTO-mediated upregulation of 
bovine PRL expression will enhance the transcription 
factors STAT3 and STAT5 in DCMECs [188]. Nota-
bly, STAT3 promotes the expression of miRNA-29 [189, 
190]. In a vicious cycle, miRNA-29-mediated suppression 
of DNMTs may epigenetically further enhance bovine 
FTO expression via FTO CpG demethylation augment-
ing lactation. Remarkably, PRL induces the expression 
of prolactin-inducible protein (PIP), a component of 
milk that is widely expressed in breast cancer (BC) and 
prostate cancer (PC) promoting cancer cell growth and 
proliferation [191–194]. Bovine milk miRNA-29b has 
been demonstrated to enhance the expression of the 
osteogenic transcription factor RUNX2 [84], which inter-
acts synergistically with androgen receptor to enhance 
PIP expression [195]. Thus, FTO-mediated activation of 
PRL expression may stimulate oncogenic signaling via 
increased PIP expression.
Bacterial and viral infections upregulate miRNA‑29
Mastitis, the inflammation of mammary glands result-
ing from bacterial infection, is a common problem in 
milk production of dairy cattle. Lipopolysaccharide 
(LPS) injection into murine lactating mammary glands 
increased the expression of STAT3 [196], promoting 
miRNA-29 expression [189, 190].
Viral infections such as papilloma virus infections as 
well enhance miRNA-29 expression via STAT3 signal-
ing [189, 190, 196–198]. It is of most critical concern 
that oncogenic bovine viruses (e.g. polyoma-, papil-
loma- or single-stranded DNA viruses) contaminate 
milk and dairy products [199–201]. Thus, unnoticed 
infection of dairy cattle may promote epigenetic 
activation of human FTO via miRNA-29-mediated 
suppression of DNMTs. Vice versa, overactivated FTO-
mediated demethylation of single-stranded DNA and 
RNA may modify oncogenic viral transcription and 
mRNA splicing [4, 124, 202, 203]. Furthermore, the 
transfer of milk exsomes, which resembles a retrovirus-
like infection, may promote the spreading of oncogenic 
bovine viruses.
FTO‑driven diseases of civilization
m6A has been identified as a conserved epitranscriptomic 
modification of eukaryotic mRNAs. Deficiency of m6A 
formation has been proven to affect circadian rhythm, 
cell meiosis, embryonic stem cell proliferation, and thus 
is implicated in obesity, cancer and other human diseases 
[130, 138, 141, 203–213]. FTO is a relevant factor for the 
development of obesity and the metabolic syndrome in 
mice [203]. As observed in Swedish men and women, 
FTO rs9939609 A-allele carriers have an increased risk 
of coronary heart disease (CHD) [214, 215]. There is evi-
dence in humans that milk consumption correlates with 
the risk of CHD [216, 217]. It is thus conceivable that 
increased FTO expression from fetal to adult life pro-
motes diseases of civilization.
Fetal macrosomia and increased birth weight
Fetal overgrowth and increased birth weight are risk fac-
tors for the development of diseases of civilization such 
as obesity [218–226]. Sébert et  al. [227] identified FTO 
as a critical factor for fetal programming of obesity-
related disorders. The authors found a significant relation 
between placental FTO gene expression and fetal weight 
at 110  days gestation [227]. In humans, FTO is highly 
expressed in the placenta and is associated with increased 
fetal weight and length [228]. Bassols et  al. [228] sug-
gested that FTO controls important genes related to 
fetal growth. Liu et  al. [58] investigated placental FTO 
expression in relation to the promoter methylation of 
FTO in a Chinese population. Intriguingly, the methyla-
tion rates of CpG11 sites were significantly decreased in 
high birth weight newborns [58]. The investigators con-
cluded that high placental FTO expression is associated 
with increased birth weight [58]. Milk exosome-medi-
ated transfer of bovine miRNA-29 and miRNA-21 may 
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via downregulation of DNMTs reduce the methylation 
of critical CpG sites of the FTO promoter explaining 
milk’s function as an epigenetic enhancer of FTO expres-
sion. The Generation R study observed the association of 
increased fetal and infant growth with an increased risk 
of obesity during early childhood [229]. A higher peak 
weight velocity, which generally occurs in the first month 
after birth, was associated with an increased risk of over-
weight and obesity at 4 years of age [229]. Accumulating 
evidence underlines that milk consumption increases 
placental, fetal and birth weight [230–232].
Increased growth trajectories in childhood
The A allele of the FTO rs9939609 SNP is associated 
with a high BMI from 5.5  years onwards [233]. Estab-
lished obesity loci including FTO affect the level and 
the rate of change in BMI at 8  years in children [234]. 
The National Health and Nutrition Examination Sur-
vey (NHANES) provided evidence that milk consump-
tion in children increases BMI [235]. Among children of 
5–10 years of age, those in the highest quartile for milk 
intake had higher BMI [236]. Notably, milk had more 
consistent positive associations with BMI than any other 
dairy product, and these are strongest among children of 
2–4 years of age [236].
Increased linear growth
FTO is highly expressed in the hypothalamus and pitui-
tary gland [1, 2, 236]. FTO controls the somatotropic 
(growth hormone-IGF-1) axis [37, 236]. Fto-deleted mice 
exhibit reduced serum levels of IGF-1 [37]. Adult obesity 
susceptibility variants including FTO conferred a faster 
tempo of height growth that was evident before puberty 
[237]. Remarkably, milk consumption is known to shift 
the prepubertal somatotropic axis [238] and increases 
growth hormone (GH) and total serum IGF-1 levels [239, 
240]. It is widely accepted that cow´s milk consumption 
accelerates linear growth in children [241]. Thus, milk 
consumption may increase the somatotropic axis in an 
FTO-dependent manner.
Early menarche and diabetes risk
By using a BMI-increasing-allele-score including FTO 
it has been demonstrated that each 1 kg/m2 increase in 
childhood BMI was predicted to result in a 6.5 % higher 
absolute risk of early menarche before age 12 years [242]. 
These findings support a causal effect of BMI on early 
menarche [242]. It is of considerable concern that early 
menarche is associated with an increased risk of T2DM 
and obesity [243, 244]. In fact, NHANES [245] provided 
evidence that higher milk intake of children is associated 
with an increased risk of early menarche. However, milk 
consumption after the age of 9 years did not predict the 
age at menarche [246], which points to a sensitive win-
dow affecting BMI-menarche interactions during early 
childhood.
Obesity
There is compelling evidence that FTO is one of the 
world´s major risk genes increasing BMI and promoting 
obesity [8–19]. Notably, carriers of the FTO risk allele 
rs8050136 have an increased risk of CHD mediated by 
BMI [247]. FTO deficiency in mice led to reduction in 
adipose tissue [213]. The association between FTO and 
fat mass in humans develops by the postnatal age of 
2  years [248]. Striking evidence underlines that FTO-
mediated mRNA demethylation regulates mRNA alter-
native splicing in the control of mitotic clonal expansion 
(MCE) resulting in adipogenesis [146, 249]. Zhang et al. 
[250] confirmed that the demethylase activity of FTO is 
required for 3T3 L1 preadipocyte differentiation. The 
level of m6A is decreased in cells overexpressing FTO 
[250].
Furthermore, the obesity-associated FTO allele 
represses mitochondrial thermogenesis in adipocyte 
precursor cells in a tissue-autonomous manner associ-
ated with a shift of energy-dissipating beige adipocytes 
to energy-storing white adipocytes [251]. FTO-defi-
cient adipocytes exhibit a reduced de novo lipogenesis 
and fourfold higher expression of uncoupling protein 1 
(UCP1, thermogenin) mRNA and protein compared with 
control cells. The upregulation of UCP1 in FTO-deficient 
adipocytes enhances mitochondrial uncoupling of the 
respiratory chain, allowing for fast substrate oxidation 
with a low rate of ATP production [252]. Thus, FTO is 
not only involved in adipocyte differentiation but also 
inhibits browning, the development of brown adipose 
tissue (BAT). BAT was believed to show rapid involu-
tion in early childhood, leaving only vestigial amounts 
in adults. However, recent evidence suggests that its 
expression in adults is far more common than previously 
appreciated [253]. Rockstroh et  al. [254] detected BAT-
like and UCP1-positive adipocytes in 10.3  % of 87 lean 
children (aged 0.3–10.7  years) and in one overweight 
infant, whereas they did not find brown adipocytes in 
obese children or adults. It is conceivable, that during the 
period of lactation milk-derived FTO signaling reduces 
UCP1 expression in BAT and thus reduces BAT-driven 
thermogenesis, a requirement for early postnatal sur-
vival. Milk (FTO)-mediated suppression of UCP1 would 
allow the generation of higher levels of ATP required for 
biosynthetic pathways during postnatal growth.
Milk provides abundant amounts of BCCAs and glu-
tamine required for FTO expression [108]. According to 
a recent epidemiological study with 177,330 individuals a 
positive association between the BMI-increasing allele of 
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FTO variant and higher dietary protein intake has been 
observed supporting the link between FTO and adiposity 
and dietary protein intake [53].
Milk via transfer of abundant BCAAs and exosomal 
miRNA-29 may thus activate FTO expression promot-
ing adipogenic transcription (Fig.  1). In fact, feeding 
commercial pasteurized cow’s milk increased BMI and 
fat mass in mice [149]. There is further evidence that 
milk consumption in children, adolescents and adults 
increases BMI and obesity [235, 255–258].
Type 2 diabetes mellitus
FTO has been confirmed as an important diabetes sus-
ceptibility locus [20–28] associated with increased pri-
mary transcript levels of FTO mRNA [14, 30]. Patients 
with the FTO risk allele showed significantly higher 
serum insulin concentrations and HOMA-IR compared 
with subjects without the risk allele [259]. Bell et al. [260] 
were the first who identified variant-CpG restricted hap-
lotype-specific methylation within the FTO T2DM and 
obesity susceptibility locus tagged by SNP rs8050136. 
Several studies identified increased expression of the 
miRNA-29 family as a biomarker for T1DM and T2DM 
[261–264]. MiRNA-29s via DNMT suppression may 
decrease the CpG methylation level of FTO in pancreatic 
β-cells. In fact, recent evidence underlines that increased 
FTO expression is related to CpG hypomethylation of 
FTO [31, 32]. Toperoff et al. [31] found that DNA meth-
ylation of a specified regulatory site in peripheral blood 
leukocytes (PBLs) is associated with impaired glucose 
metabolism and T2DM. Dayeh et al. [32] identified 1649 
CpG sites and 853 genes, including FTO with differen-
tial DNA methylation in T2DM islets. FTO methylation 
in human pancreatic β-cells of non-diabetic patients 
differed significantly from FTO methylation of T2DM 
patients, respectively [32]. Modest differences in DNA 
methylation of individual CpG sites may exert big effects 
on gene expression over long periods of time [31, 32]. As 
DNA hypomethylation commonly increases gene activity 
[54], it is conceivable that CpG hypomethylation of FTO 
in T2DM pancreatic β-cells may decrease m6A methyla-
tion of mRNAs. Indeed, Shen et  al. [265] demonstrated 
that the m6A contents in the RNA from T2DM patients 
and diabetic rats were significantly lower compared with 
controls. The mRNA expression level of FTO was signifi-
cantly higher in T2DM patients than that of the controls 
and was associated with the risk of T2DM. Moreover, the 
m6A contents were inversely correlated with FTO mRNA 
expression [265].
There is recent evidence that FTO overexpression is 
also involved gluconeogenesis associated with upregu-
lation of mRNA expression of the rate-limiting gluco-
neogenic enzymes glucose-6-phosphatase (G6P) and 
mitochondrial phosphoenolpyruvate carboxykinase 
(PEPCK) [266]. FTO overexpression resulted in increased 
mRNA and protein expression of CCAAT/enhancer-
binding protein-β (C/EBPβ), which promotes G6P and 
PEPCK expression [266]. Notably, C/EBPβ activates 
expression of C/EBPα and PPAR-γ, which further drives 
the adipocyte phenotype [267] after FTO-driven mitotic 
clonal expansion (MCE) of adipocytes [146, 249, 250]. 
Thus, FTO counteracts the activity of metformin, which 
inhibits gluconeogenesis and adipogenesis, whereas 
FTO overexpression upregulates gluconeogenesis and 
adipogenesis.
Interestingly, FTO mRNA levels were increased in sub-
cutaneous adipose tissue (SAT) of T2DM patients, and 
treatment with Rosiglitazone improved insulin sensitiv-
ity and reduced SAT FTO mRNA levels [268]. SAT FTO 
mRNA and protein levels were increased in insulin resist-
ant women (high HOMA) compared to insulin sensitive 
women (low HOMA) [268]. Furthermore, FTO expres-
sion was transiently increased in early 3T3-L1 adipocyte 
differentiation, which coincides with the induction of 
PPARγ2 expression [268]. There is compelling evidence 
that omental adipose tissue (OAT) FTO expression is 
associated with adiposity, whereas SAT FTO expression 
is associated with insulin resistance [268].
Remarkably, the EPIC-InterAct Study (n  =  340,234) 
provided evidence for an increased T2DM risk in asso-
ciation with milk consumption in contrast to other dairy 
products [269]. Obviously, it is a fundamental func-
tion of milk to increase FTO-dependent β-cell mRNA 
transcription and insulin production, which drive 
mTORC1-dependent translation [39]. However, persis-
tent milk-mediated activation of β-cell transcription and 
translation will induce premature aging and β-cell endo-
plasmic reticulum (ER) stress promoting early onset of 
T2DM [264]. Notably, high intakes of milk, but not meat, 
increase serum insulin levels and insulin resistance in 
8-year-old boys [270]. Early insulin resistance is com-
monly treated with the anti-diabetic drug metformin, 
which is a multifunctional inhibitor of mTORC1 [271]. 
Remarkably, metformin has recently been shown to 
induce DNA methylation [272], thus may directly coun-
teract milk-mediated epigenetic upregulation of FTO 
expression.
Cancer
FTO polymorphisms can regulate the expression of genes 
at large kilobases of distance as well as the expression of 
FTO itself, and regions for transcription factor binding. 
To date it has been observed that variants rs9939609, 
rs17817449, rs8050136, rs1477196, rs6499640, 
rs16953002, rs11075995 and rs1121980 are associated 
with the risk of developing cancer [273].
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There is recent interest in the role of m6A mRNA 
methylation in stem cell and cancer stem cell homeosta-
sis [204–207, 212]. m6A RNA methylation is required to 
maintain mouse embryonic stem cells in their ground 
state [207]. Loss of m6A methylation is associated with a 
loss of self-renewal capability [207]. m6A RNA methyla-
tion is regulated by miRNAs and promotes reprogram-
ming to pluripotency [209].
Long interspersed element 1 (L1) retrotransposon 
mobilization occurs exclusively in cancers of epithelial 
origin [274]. According to a recent hypothesis L1 pro-
moter hypomethylation is correlated with epithelial to 
mesenchymal transition (EMT) promoting metasta-
sis. Furthermore, human L1 retrotransposition, which 
is dependent on RNA intermediates, is associated with 
genetic instability [275]. Milk-derived miRNA-29s via 
DNMT suppression may be involved in L1 hypomethyla-
tion and L1 activation promoting cancer initiation and 
progression.
Prostate cancer
Prostate cancer (PC) is the most common cancer of men 
in Western societies. The rs9939609 A allele, which was 
associated with higher BMI, was positively associated 
with high-grade PC [276]. Machiela et  al. [277] identi-
fied 10 T2DM markers including FTO that were associ-
ated with increased risk for PC. This points to a common 
genetic or epigenetic basis of T2DM and PC. In fact, 
an association of T2DM and PC has recently been con-
firmed in American Indians [278]. During a mean fol-
low-up of 8.5 years, 2446 men of 129,502 participants of 
the EPIC study developed PC. Waist circumference and 
waist-hip ratio were positively associated with risk of 
advanced disease [279].
There is compelling evidence that total dairy protein 
intake is related to PC risk [280]. According to the EPIC 
(n = 142,251) daily intake of 35 g dairy protein increased 
PC risk by 32 % [280]. The Physicians’ Health study pro-
vided evidence that only whole milk was consistently 
associated with higher incidence of fatal PC in the entire 
cohort and higher PC-specific mortality among cases 
[281]. In fact, feeding reconstituted milk protein powder 
but not whole milk in two mouse models of benign and 
neoplastic lesions did not promote PC progression [282]. 
Notably, daily milk consumption in adolescence (vs. less 
than daily), but not in midlife or currently, was associ-
ated with a 3.2-fold risk of advanced PC in the popula-
tion-based Iceland cohort of 8894 men [283]. Thus, there 
is good reason to suggest that milk-mediated upregula-
tion of FTO increases transcriptional activity driving 
an mRNA landscape for the development and progres-
sion of PC during childhood and adolescence. Moreo-
ver, milk-mediated epigenetic activation of FTO may be 
linked to FTO-driven activation of mTORC1 [110], which 
is closely involved in the pathogenesis of PC [284, 285]. 
Indeed, cow’s milk stimulated the growth of LNCaP cells 
producing an average increase in cancer cell growth rate 
of over 30  % [286]. Furthermore, FTO-mediated upreg-
ulation of PRL may enhance oncogenic PIP expression 
[192, 193]. There is accumulating evidence for the ben-
eficial effect of metformin in the treatment and preven-
tion of PC, especially in patients with T2DM [287–290]. 
Metformin´s anti-cancer effects may be traced back to its 
capability to methylate DNA [272], which may attenuate 
FTO-PRL-PIP well as FTO-mTORC1 signaling.
Breast cancer
Breast cancer (BC) is the most common cancer of women 
in Western societies and is often associated with obesity 
[291]. A recent epigenome-wide association study reveals 
decreased average methylation levels years before BC 
diagnosis [292].
Genome-wide SNP studies strongly suggest that the 
FTO locus is associated with estrogen receptor (ER)-
negative BC [293]. This signal is tagged by rs11075995, 
located in a 40  kb LD block in intron 1 of FTO, within 
an enhancer region that appears to be active in both 
normal and triple-negative BC cells. da Cunha et  al. 
[294] observed a 4.59-fold increased risk for women 
who have the allele combination FTO rs1121980/FTO 
rs9939609/MC4R rs17782313 indicating an interaction 
between FTO and MC4R polymorphisms in BC devel-
opment. FTO rs16953002 AA genotype conferred sig-
nificant increased BC risk compared to GG genotype in 
a Chinese population [295]. In another Chinese study 
5 susceptibility loci including FTO correlated with BC 
[296]. Of 41 recently discovered BC susceptibility vari-
ants, associations were found between rs1432679 (EBF1), 
rs17817449 (MIR1972-2: FTO), rs12710696 (2p24.1), 
and rs3757318 (ESR1) and adjusted absolute and percent 
mammographic dense areas, respectively [297]. Singh 
et al. presented a BC cell model featuring an embryo-like 
gene expression with amplification of FTO [298]. Thus, 
substantial evidence links FTO to pathogenesis of BC or 
subtypes of BC.
From 1916 to 1975, BC risk increased 2.7-times in Nor-
way and has been associated with changes of life style 
factors after World War II including milk intake [299]. 
In fact, women consuming 0.75 L or more of full-fat milk 
daily had a relative risk of 2.91 compared with those who 
consumed 0.15  L or less [300]. Remarkably, consump-
tion of commercial whole and non-fat milk increased the 
incidence of 7,12-dimethylbenz(a)anthracene (DMBA)-
induced mammary tumors in rats [301]. Tumor numbers, 
volume and incidence doubled after 20  weeks of milk 
consumption in these DMBA-induced mammary tumors 
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[301]. Notably, PRL binding to DMBA-induced mam-
mary tumors was three times higher than that observed 
in lactating mammary glands of the rat [302, 303]. Fur-
ther administration of PRL enhanced tumor growth 
[302, 303], whereas pharmacological suppression of PRL 
secretion inhibited DMBA-induced mammary carcino-
genesis in the rat [304]. It is of critical concern that large 
prospective epidemiological studies show correlations 
between circulating levels of PRL with an increased risk 
of ER-positive invasive BC [305].
Breastfeeding apparently meets the appropriate spe-
cies-specific signaling axis of FTO- and mTORC1-medi-
ated postnatal programming. Women, who had been 
breast-fed have a reduced lifetime risk of developing BC 
[306]. Breastfeeding reduces the risk of developing BC 
[307], specifically of triple-negative BC [308].
A large Swedish cohort study demonstrated that peo-
ple with lactose intolerance and low consumption of 
milk and other dairy products had a decreased risk of 
BC, lung, and ovarian cancers [309]. These data imply 
that cow´s milk consumption increases transcription, 
translation and cell proliferation in BC. Notably, there is 
preliminary evidence that metformin treatment reduces 
BC recurrence in T2DM patients [310, 311]. Metformin-
induced DNA methylation [272] may reduce FTO-PRL 
signaling that increases PIP expression in BC [192, 193]. 
Remarkably, PIP regulates proliferation of luminal A type 
BC cells in an ER-independent manner [312], supporting 
the role of FTO in ER-negative BC [293].
Neurodegenerative diseases
Environmental factors such as diet contribute signifi-
cantly to risk of Alzheimer’s disease (AD) and Parkin-
son’s disease (PD) [313]. Accumulating evidence points 
to the important role of dietary epigenetic regulation in 
the pathophysiology of AD [314–316]. AD and PD are 
both tauopathies. mTORC1 induces abnormally hyper-
phosphorylated tau proteins, which aggregate resulting 
in compromised microtubule stability [317]. mTORC1 
is involved in regulating tau distribution in subcellular 
organelles and in the initiation of tau secretion from cells 
to extracellular space [318]. Notably, FTO via LRS plays a 
crucial role for mTORC1 activation [110].
Carriers of common FTO polymorphisms rs9939609 
A allele exhibit a reduction in frontal lobe volume of the 
brain and an impaired verbal fluency performance [319, 
320]. A population-based study from Sweden found that 
carriers of the FTO rs9939609 A allele have an increased 
risk for incident AD [320]. Furthermore, an interaction 
between FTO and APOE was found, with increased risk 
for dementia for those carrying both FTO AA and APOE 
ϵ4 [321]. Genetic variation in introns 1 and 2 of the 
FTO gene may contribute to AD risk [322]. Remarkably, 
impaired satiation and increased feeding behavior has 
been reported in the triple-transgenic AD mouse model 
[323], which may point to increased FTO expression.
A dietary pattern associated with a lower AD risk 
was characterized by higher intakes of salads, nuts, fish, 
tomatoes, poultry, cruciferous vegetables, fruits, and dark 
and green leafy vegetables and a lower intake of high-fat 
dairy products, red meat, organ meat, and butter [324].
Overweight is more prevalent in PD patients [325, 326]. 
In early PD, weight gain was revealed over 3 years accom-
panied by an increase in fat mass and waist circumfer-
ence [327]. Whereas FTO gene polymorphisms have not 
yet been studied in PD patients, several studies show an 
association between milk consumption and the risk of 
PD [328–333]. DNA methylation plays a pivotal role in 
the pathogenesis of age-related neurodegeneration and 
cognitive defects [334]. Milk-miRNA-29-mediated sup-
pression of DNA methylation and FTO-enhanced mRNA 
m6A demethylation via persistent milk consumption may 
thus play an important role in the pathogenesis of neuro-
degenerative diseases.
Future prospects
The continuous interaction between the individual´s 
genetic makeup and environmental factors such as early 
nutrition result in a spectrum of states ranging from 
healthy aging to age-related diseases of civilization [102–
104, 335]. Milk is a highly specialized nutrient and sign-
aling system of mammalian evolution that apparently 
shapes the epitranscriptome of the milk recipient via 
FTO-mediated modifications of RNA nucleotides. Future 
research should unravel milk´s biological impact on the 
recently recognized dual axis of coordinated regulation 
between the genome and the epigenome and the tran-
scriptome and the epitranscriptome, respectively [336]. 
More scientific insights into milk’s epigenetic signature, 
which links the maternal lactation genome to the infant’s 
epitranscriptome as well as the impact of pasteurized 
cow’s milk on the epitranscriptome of the milk consumer 
will allow a deeper understanding of milk-mediated post-
natal programming as well as the pathogenesis of West-
ern diseases of civilization.
Conclusions
Early-life experiences play a critical role for lifelong 
metabolic programming. Current research focuses on 
the role of epigenetic causes of excess adult weight gain 
and early onset of age-related diseases [337]. Impor-
tantly, the FTO gene has been recognized to play a cru-
cial role in the early-life determination of body weight, 
body composition and energy balance [337]. Milk is the 
early nutritional environment and life experience of all 
mammals. There is increasing evidence that milk is not 
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“just food” but represents a sophisticated signaling sys-
tem of mammals to promote anabolism for postnatal 
mTORC1-mediated growth [38]. It has recently been 
demonstrated that milk stimulates mTORC1-dependent 
translation [39], a pivotal requirement for cell growth 
and proliferation. There is overwhelming evidence that 
the well-preserved gene FTO plays a predominant role 
in DNA demethylation and m6A-dependent mRNA 
demethylation [1, 4, 125, 129–132]. Thus, FTO pro-
motes transcription and increases genomic transcrip-
tional activity, a requirement for postnatal growth. 
Milk functions apparently as an “epigenetic interface” 
generated by the lactation genome that controls the 
FTO-dependent transcriptome of the milk recipient 
(Fig.  1). FTO is thus an evolutionary checkpoint coor-
dinating the program of the lactation driving tran-
scription, translation and anabolism of the newborn 
mammal. FTO-mediated demethylation of mRNAs 
increases transcriptional activity and generates mRNA 
splice variants that are critically involved in adipogen-
esis [144–146], ghrelin-regulated appetite control [150], 
and LRS-mediated mTORC1 activation [110, 157–162] 
(Fig. 2).
Remarkably, FTO plays a critical role in milk produc-
tion. The mRNA of PRL, the most important hormone 
promoting lactation, is regulated via m6A methylation 
[180, 186] and thus depends on FTO activity. In this con-
text it is not surprising that bovine FTO variants enhance 
lactation performance [164]. Moreover, enhanced expres-
sion of miRNA-29 in DCMECs increases milk yield [180]. 
Abundance of miRNA-29s in DCMECs of high perfor-
mance dairy cows may downregulate DNMT-mediated 
methylation of bovine FTO, thereby increasing bovine 
FTO mRNA and protein levels of DCMECs. Bovine 
miRNA-29s, which are identical with human miRNA-
29s, and bovine FTO mRNA, which is highly homolo-
gous to human FTO mRNA, may reach the consumer of 
pasteurized fresh milk via uptake of milk exosomes [84]. 
Viral and bacterial infections of dairy cows may further 
increase miRNA-29 levels [189, 190, 196–201] (Fig.  1). 
Thus, the efforts of veterinary medicine intensifying 
lactation performance and milk yield apparently over-
stimulate FTO signaling of the human milk consumer, 
an overlooked interaction in the pathogenesis of West-
ern diseases. The presented working model allows a new 
understanding of milk as mammal´s temporal amplifier 
of the epitranscriptome of the milk recipient. m6A is a 
common modification of mRNA with potential roles in 
fine-tuning the RNA life cycle and mRNA expression 
control [143, 338]. Milk-activated FTO operates as a 
methylation “eraser” to promote transcription and trans-
lation for adequate growth during the lactation period 
[129, 143]. It is conceivable that individuals carrying obe-
sigenic genetic FTO variants with increased FTO expres-
sion may be even more susceptible to milk-mediated 
epigenetic activation of FTO. FTO should be regarded as 
Overexpression of FTO  
 m6A RNA demethylase 
        Increase in mRNA stability,  reduction of mRNA degradation  
    Modification of mRNA splicing, formation of splicing variants 
       Alteration of miRNA-mRNA binding and miRNA biogenesis 
    Adipogenesis via generation of RUNX1T1 short splicing isoform 
  Adipogenesis via upregulation of C/EBPβ C/EBPα   PPARγ 
  Gluconeogenesis with increased expression of G6P and PEPCK 
  Upregulation of ghrelin mRNA  appetite  and feeding reward 
Upregulation of the mTORC1 activator LRS  increased translation  
Upregulation of PRL mRNA, PRL  STAT3  miRNA-29 biogenesis 
       Reduced expression of UCP1 mRNA    thermogenesis 
                            and reduced development of BAT
Modification of circadian rhythms suppression of CLOCK BMAL 1  
     Accelerated aging with decrease in leukocyte telomere length  
Fig. 2 Synopsis of m6A mRNA modifications induced by increased FTO expression. The RNA m6A eraser FTO drives crucial epigenetic mechanisms 
fundamentally involved in the pathogenesis of diseases of civilization
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the driver of the transcriptome, whereas mTORC1 drives 
the translational machinery interconnected via an FTO-
mTORC1 crosstalk.
Persistent milk-mediated epigenetic FTO signaling may 
explain the epidemic of age-related diseases of civiliza-
tion. It is thus not surprising that an increased mortality 
in relation to high milk intake has recently been observed 
in a Swedish cohort of men and women [339]. The antag-
onistic pleiotropy theory of aging postulates that genes 
beneficial early in life operate at the cost of aging when 
persistently activated later in life [340]. Persistent over-
activation of evolutionary developmental genes, such as 
FTO and MTOR, which are most important for perina-
tal programming, appear to be the major health hazard 
promoting aging and early onset of age-related diseases. 
In fact, obesity-related risk allele carriers of FTO gene 
show dose-dependent increments in BMI during aging. 
Moreover, the obesity-related risk allele is associated 
with reduced medial prefrontal cortical function during 
aging [341]. In addition, presence of the FTO rs9939609 
polymorphism risk allele in a Korean population was 
inversely associated with leukocyte telomere length 
[342].
Future research should characterize the epigenetic 
FTO-activating potential of milk versus other fermented 
dairy products. The relative contribution of milk-derived 
regulatory mechanisms that activate FTO expres-
sion such as BCAAs and exosomal miRNAs, have to be 
determined in detail. It is of critical interest to provide 
experimental evidence showing that milk consump-
tion modifies the FTO methylation status resulting in 
increased FTO expression and activity. Furthermore, it is 
important to study differences in epigenetic FTO activa-
tion levels between human breast milk, bovine milk, and 
commercial milk of high performance dairy cows. Spe-
cial attention should be paid to the effects of bovine milk 
exosomal miRNAs and mRNAs in the epigenetic control 
of FTO expression during sensitive periods of pre- and 
postnatal FTO-mediated metabolic programming.
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